Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Amag Pharma to Spend $675M on Lumara Health

By Pharmaceutical Processing | September 29, 2014

WALTHAM, Mass. (AP) — Shares of anemia treatment maker Amag Pharmaceuticals soared Monday after it announced plans to buy Lumara Health in a cash-and-stock deal that could be worth more than $1 billion.

The Waltham, Massachusetts, company said Monday it will spend $600 million in cash and another $75 million in stock on the privately held Lumara, which makes Makena, a treatment designed to reduce the risk of premature birth.

Amag also could pay an additional $350 million if certain sales milestones are reached. Lumara Health in based in Chesterfield, Missouri.

Amag President and CEO William Heiden said in a statement that the deal gives his company an attractive new therapeutic area and fits well with their expansion plans for Amag’s anemia treatment Feraheme.

Makena generated more than $130 million in sales over the 12-month period that ended Aug. 31. It aims to reduce the risk of a premature birth in women who have previously had a spontaneous, premature delivery.

The deal has been approved by the boards of directors of both companies and Lumara shareholders. The companies expect to complete it in the fourth quarter.

Shares of Amag Pharmaceuticals Inc. were up more than 15 percent, or $3.57 per share, to $26.75 more than an hour before markets opened Monday. The stock had slipped about 5 percent so far this year, as of Friday’s market close.

Related Articles Read More >

Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Wyzo
Wyzo high-speed pick-and-place sidebot wins design awards
Purdue University
Purdue University launches institute for advanced manufacturing of pharmaceuticals

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards